TheraRadar
← Back
Data updated: Jun 28, 2026

PENN LIFE

Generics

PENN LIFE is a generic drug manufacturer focused on Oncology.

2019
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

PENN LIFE's Key Drugs

PENN LIFE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PENN LIFE's Recent FDA Approvals

New NDA/BLA approvals for PENN LIFE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PENN LIFE's Therapeutic Areas

PENN LIFE's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%
2 drugs

PENN LIFE's Top Competitors

PENN LIFE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

PENN LIFE Pipeline Snapshot

Active clinical trials for PENN LIFE across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling